Long-term neurocognitive effects of antipsychotics in schizophrenia: A network meta-analysis

European Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2014, Pages 127-134

  Desamericq G ^a,b,c,d   Schurhoff, F ^a,b,c   Meary, A ^a,b,c   Szoke A ^a,b,c   Macquin Mavier, I ^b,c   Bachoud Levi A C ^a,b,c,d   Maison, P ^a,b,c,d  

^a INSERM U955   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d ECOLE NORMALE SUPÉRIEURE   (France)

Author keywords

Antipsychotic; Cognition; Meta analysis; Neuropsychology; Schizophrenia

Indexed keywords

ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; HUMANS; SCHIZOPHRENIA;

EID: 84895075618     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1600-y     Document Type: Review

References (32)

1. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-445
2. Keefe RSE, Eesley CE, Poe MP (2005) Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57:688-691. doi: 10.1016/j.biopsych.2005.01.003
3. Bilder RM, Goldman RS, Robinson D et al (2000) Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157:549-559
4. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330
5. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26:119-136
6. Harvey PD, Howanitz E, Parrella M et al (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155:1080-1086
7. Harvey PD, Green MF, Keefe RSE, Velligan DI (2004) Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 65:361-372
8. Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299:350-351. doi: 10.1126/science.1077141
9. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201-222
10. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55:1013-1022. doi: 10.1016/j.biopsych. 2004.01.027
11. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472. doi: 10.1017/S146114570500516X
12. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer W (2006) The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol (Oxford) 20:335-346. doi: 10.1177/0269881105057002
13. Davidson M, Galderisi S, Weiser M et al (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675-682. doi: 10.1176/appi.ajp.2008.08060806
14. Keefe RSE, Bilder RM, Davis SM et al (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633-647. doi: 10.1001/archpsyc.64.6.633
15. Keefe RSE, Sweeney JA, Gu H et al (2007) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1061-1071. doi: 10.1176/appi.ajp.164.7.1061
16. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
17. Lumley T (2002) Network meta-analysis for indirect treatment comparisons. Stat Med 21:2313-2324. doi: 10.1002/sim.1201
18. Guilera G, Pino O, Gómez-Benito J, Rojo JE (2009) Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials. Eur J Psychiatry 23:77-89. doi: 10.4321/S0213-61632009000200002
19. Keefe RSE, Seidman LJ, Christensen BK et al (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985-995
20. Keefe RSE, Seidman LJ, Christensen BK et al (2006) Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 59:97-105. doi: 10.1016/j.biopsych.2005.06.022
21. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2007) A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89:211-224. doi: 10.1016/j.schres.2006.08.021
22. Guo X, Zhai J, Wei Q et al (2011) Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 503:141-146. doi: 10.1016/j.neulet.2011.08.027
23. Andersen R, Fagerlund B, Rasmussen H et al (2011) Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Res 187:49-54. doi: 10.1016/j.psychres. 2010.10.013
24. Basso MR, Bornstein RA, Lang JM (1999) Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 13:283-292. doi: 10.1076/clin.13.3.283.1743
25. Szöke A, Trandafir A, Dupont M-E et al (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 192:248-257. doi: 10.1192/bjp.bp.106.029009
26. Crespo-Facorro B, Rodríguez-Sánchez JM, Pérez-Iglesias R et al (2009) Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 70:717-729. doi: 10.4088/JCP.08m04634
27. Baldwin D, Woods R, Lawson R, Taylor D (2011) Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199
28. Riedel M, Schennach-Wolff R, Musil R et al (2010) Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol 25:116-125. doi: 10.1002/hup.1101
29. Purdon SE, Jones BD, Stip E et al (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57:249-258
30. Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26:137-149
31. Rosenheck R, Perlick D, Bingham S et al (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693-2702. doi: 10.1001/jama.290.20.2693
32. Cuesta MJ, Jalón EG, Campos MS, Peralta V (2009) Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 194:439-445. doi: 10.1192/bjp.bp.108.055137